+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anti Tumour Necrosis Factor"

TRAIL Receptor 2 Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

TRAIL Receptor 2 Agonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Cryoprin-Associated Periodic Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Cryoprin-Associated Periodic Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Rituximab - Global Strategic Business Report - Product Thumbnail Image

Rituximab - Global Strategic Business Report

  • Report
  • September 2025
  • 378 Pages
  • Global
From
Autoimmune Drugs - Global Strategic Business Report - Product Thumbnail Image

Autoimmune Drugs - Global Strategic Business Report

  • Report
  • September 2025
  • 287 Pages
  • Global
From
Axial Spondyloarthritis (AXSPA) - Global Strategic Business Report - Product Thumbnail Image

Axial Spondyloarthritis (AXSPA) - Global Strategic Business Report

  • Report
  • September 2025
  • 182 Pages
  • Global
From
Methotrexate Drugs - Global Strategic Business Report - Product Thumbnail Image

Methotrexate Drugs - Global Strategic Business Report

  • Report
  • September 2025
  • 564 Pages
  • Global
From
Psoriatic Arthritis Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Psoriatic Arthritis Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 276 Pages
  • Global
From
Uveitis Drugs - Global Strategic Business Report - Product Thumbnail Image

Uveitis Drugs - Global Strategic Business Report

  • Report
  • September 2025
  • 413 Pages
  • Global
From
From
Ulcerative Colitis Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Ulcerative Colitis Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 181 Pages
  • Global
From
Crohn`s Disease (CD) Therapy - Global Strategic Business Report - Product Thumbnail Image

Crohn`s Disease (CD) Therapy - Global Strategic Business Report

  • Report
  • September 2025
  • 142 Pages
  • Global
From
Immunosuppressants - Global Strategic Business Report - Product Thumbnail Image

Immunosuppressants - Global Strategic Business Report

  • Report
  • September 2025
  • 349 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • September 2025
  • 193 Pages
  • Global
From
From
Autoimmune Disease Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Autoimmune Disease Therapeutics - Global Strategic Business Report

  • Report
  • September 2025
  • 456 Pages
  • Global
From
Psoriasis Treatment - Global Strategic Business Report - Product Thumbnail Image

Psoriasis Treatment - Global Strategic Business Report

  • Report
  • September 2025
  • 193 Pages
  • Global
From
Ulcerative Colitis - Pipeline Insight, 2025 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Loading Indicator

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications. The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more